XXE97U7 – Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
Coding Notes
Active
Billable, valid for HIPAA-covered transactions
PCS Table
|
Section
X
New Technology
|
|||
|
Body System
X
Physiological Systems
|
|||
|
Operation
E
Measurement
|
|||
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|
0
Central Nervous
|
X
External
|
0
Intracranial Vascular Activity, Computer-aided Assessment
|
7
New Technology Group 7
|
|
3
Arterial
|
X
External
|
2
Pulmonary Artery Flow, Computer-aided Triage and Notification
|
7
New Technology Group 7
|
|
5
Circulatory
|
X
External
|
M
Infection, Whole Blood Nucleic Acid-base Microbial Detection
|
5
New Technology Group 5
|
|
5
Circulatory
|
X
External
|
N
Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility
|
6
New Technology Group 6
|
|
5
Circulatory
|
X
External
|
R
Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure
T
Intracranial Arterial Flow, Whole Blood mRNA
V
Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection
|
7
New Technology Group 7
|
|
9
Nose
|
7
Via Natural or Artificial Opening
|
U
Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction
|
7
New Technology Group 7
|
|
B
Respiratory
|
X
External
|
Q
Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection
|
6
New Technology Group 6
|